Company Name
Suzhou Lixin Pharmaceutical Co., Ltd
Year of Establishment
2000
Annual Turnover(USD)
500,000 to 99,999,999
Company Introduction
Since its establishment in 2000, Lixin Pharmaceutical Co., Ltd. has adhered to the goal of serving the global regulatory pharmaceutical market. Through technological innovation and standardized management, the company is continually developing and producing high-quality APIs and intermediates to meet the human pursuit of high-quality drugs.
Adhering to corporate culture of scientific, rigorous, and standardized, advocating the spirit of innovation, and focus on the development and application of safety, environmental-friendly, low consumption, and high-quality original process technologies, Lixin Pharmaceutical has gradually established the production lines in the fields of anti-tumor, cardiovascular, antiviral, and digestive systems. Lixin has over 30 international invention patents in China, the United States, Europe, and other regions, forming a company-own intellectual property system. Lixin has submitted 4 DMF of API to US FDA, and obtained 8 CEP, NMPA new drug certificates, and over 20 domestic GMP certificates. Meanwhile, more than 20 products are under development for both domestic and foreign market, which laying a solid foundation for the company's sustainable development.
Lixin Pharmaceutical adheres to the implementation of a globally standardized GMP management system and continuously improves and pursues excellence. The company has a R&D center with a total area of over 3000 square meters. There are two GMP factories located in Suzhou city of Jiangsu province and Zibo city of Shandong province. Both factories have multiple GMP workshops and professional APIs production lines, equipped with advanced sewage treatment systems and other supporting facilities. The factories have passed multiple inspections by NMPA, US FDA, EDQM, and EMA, and will provide high-quality services to global pharmaceutical companies through a sustainable and healthy development philosophy.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Other Competitive Advantages
Professional:Professional and experienced regulations, patents and sales teams provide end customers with a full range of professional services.
Factory:We will firmly control from the starting material to the final product, give full play to the advantages of the entire industry chain, and form advantages in terms of material cost and management cost through large-scale production.
Technical:With many years of technology accumulation and continuous investment, it has a number of patented core technologies; a variety of research and development pipelines to promote product upgrades and process upgrades through continuous innovation.
Dedicated:Dedicated production line of different types of products to ensure compliance and quality control, improve product competitiveness.
Patents and Copyright
Dozens including international PCT patents.
Patent authorization for inventions in the US, Europe and China.
Obtained government awards and peer recognition.
Milestone
In 2000, Lixin Pharmaceutical Co., Ltd. was officially established. In 2009, obtained the first new drug certificate. In 2010, the US FDA conducted on-site inspection. In 2012, the first CEP certificate was obtained. In 2016, EMA and EDQM conducted on-site inspection. In 2017, Shandong Lixin established. In 2022,Shandong Lixin won the first CEP certificate.